• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Sciences

    Nexalin Publishes Neuroimaging Data On Chronic Insomnia Therapy

    GLOBENEWSWIRE

    Nexalin Study Reveals DIFS Tech Cuts Self-Injury, Depression

    GLOBENEWSWIRE

    Nexalin Launches NeuroCare for Alzheimer`s and Mood Disorders

    GLOBENEWSWIRE

    Nexalin Showcases Leading DIFS Neuroimaging Research

    GLOBENEWSWIRE

    Nexalin Wraps FDA Q-Submission For Gen-2 SYNC Neurostimulation

    GLOBENEWSWIRE

    Nexalin 15mA Device Aids Comorbid Gambling, Alcohol Treatment

    GLOBENEWSWIRE

    Nexalin Tech Gets Approval To Sell Gen 2 SYNC, DIFS Device

    GLOBENEWSWIRE

    Nexalin DIFS Tech Improves Cognition, Brain Network in Alzheimer

    GLOBENEWSWIRE

    Nexalin Tech Appoints Dr. Robert Rothstein To Board

    GLOBENEWSWIRE

    Nexalin Tech Reports More Positive Results in Alzheimer Disease

    GLOBENEWSWIRE

    Nexalin Tech Issues U.s. Patent For Halo™ Clarity Device

    GLOBENEWSWIRE

    Nexalin Technology Hosts Live Investor Webinar on September 9

    GLOBENEWSWIRE

    Nexalin Technology`s Live Investor Webinar & Q&A on June 3

    GLOBENEWSWIRE

    Nexalin Technology Gets IRB Approval in Brazil for Anxiety

    GLOBENEWSWIRE

    Nexalin Supports Health Tech Act for AI-Enabled Devices

    GLOBENEWSWIRE

    Nexalin Technology Enrolls First Patients in UCSD Clinical Trial

    GLOBENEWSWIRE

    Peer-Reviewed Study Validate Nexalin`s DIFS Technology in Neuromode

    GLOBENEWSWIRE

    Nexalin Technology Study on Alzheimer’s Published in Journal

    #N/A

    Study Shows Nexalin’s DIFS Improves Memory In Alzheimer’s Patients

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.